The interrogation of clinical samples alongside in vitro and in vivo experiments in transgenic and PDX mouse models of BC demonstrates the potential of therapeutic intervention for TNBC patients by specifically targeting the tumorigenic LGR5+ tumor initiating cells. The gene discussed is LGR5; the disease is neoplasm.